Fatty liver: with retatrutide, 86% normalised their liver fat

Phase 2a substudy in Nature Medicine: liver fat fell by more than 80% at higher doses in 24 weeks.

In this randomised, double-blind substudy, 98 people with metabolic dysfunction-associated steatotic liver disease received weekly retatrutide (1, 4, 8 or 12 mg) or placebo for 48 weeks.

At 24 weeks, liver fat fell by 81.4% with 8 mg and 82.4% with 12 mg, versus a 0.3% increase with placebo. Normal levels, below 5%, were reached by 79% with 8 mg and 86% with 12 mg; none with placebo.

In three points

Phase 2a human study, double-blind
Liver fat −82.4% with 12 mg at 24 weeks
86% returned to normal liver fat levels

Compounds mentioned

Retatrutide

Original source: Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
PubMed · Nature Medicine

Plain-language summary by SYNTRA LABS based on the original publication and checked against its source. It is not medical advice or a recommendation for use. SYNTRA LABS compounds are for research use only and not for human consumption.